Restore Medical Ltd., a clinical-stage medtech company based in Or Yehuda that develops cardiac implants for the treatment of congestive heart failure (CHF), announced on Wednesday promising preliminary results of the First-in-Human clinical trial of ContraBand, its breakthrough treatment for patients suffering from CHF.
Follow Israel Hayom on Facebook and Twitter
The minimally-invasive, catheter-delivered implants are used to treat patients with chronic left ventricular failure, where the heart is unable to pump sufficient oxygen-rich blood through the body.
Restore Medical has successfully implanted the ContraBand in its first patients at the ZNA medical center in Middelheim, Antwerp, Belgium, followed by Kaplan Medical Center in Israel.
The ContraBand is expected to relieve symptoms and improve patients' quality of life by causing the healthy right ventricle to assist the failing left ventricle. The function of the implants is fully reversible even long after the procedure, a feature unique in the field of cardiovascular implants.
"These first procedures are milestones in proving the ContraBand technology to be both safe and effective for heart failure patients," said Restore Medical CEO Gilad Marom. "The positive impact this treatment can have on the millions of people suffering from CHF cannot be underestimated. Not only will it transform the quality of life of treated patients, but it will also reduce the enormous financial burden that comes as a result of patients being undertreated."
